- CytomX Therapeutics ( NASDAQ: CTMX ) on Wednesday said its phase 2 trial of its antibody praluzatamab ravtansine in breast cancer patients met the main goal of the study.
- CTMX said the study met the primary endpoint of objective response rate of greater than 10% in HR+/HER2-non-amplified breast cancer .
- The study showed a clinical benefit rate of 40% and the patients showed a median progression-free survival of 2.6 months.
- However, in arm B of the study, the objective response rate was less than 10% in patients with advanced triple-negative breast cancer.
- Subsequently, CTMX said enrollment in arms B and C of the study will be discontinued.
- CTMX CEO Sean McCarthy also said that the company does not plan to further advance the praluzatamab ravtansine program alone due to current market conditions and will seek a partner.
- CTMX stock earlier closed +1.6% at $1.97.
For further details see:
CytomX says phase 2 study of breast cancer antibody treatment met main goal